Trial Profile
A Phase 1/2a Study to Evaluate Safety and Efficacy of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2018
Price :
$35
*
At a glance
- Drugs Vax-DC/MM (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Adverse reactions
- 16 Jul 2018 New trial record
- 10 Jan 2017 Results published in the Oncotarget